肿瘤标志物癌胚抗原cea与egfr-tki药物治疗.docVIP

非小细胞肺癌血清CEA水平与EGFR-TKI疗效关系 李醒亚1，成媛1，刘杰1，张中冕2，周云3，马智勇4，申淑景5，贾永旭1 （450052 郑州，郑州大学第一附属医院肿瘤科1；450052 郑州，郑州大学第二附属医院肿瘤科2; 450052 郑州，河南省人民医院肿瘤科3；450052 郑州，河南省肿瘤医院4；450052 郑州，郑州大学第一附属医院放疗科5） 摘要: 目的 本研究旨在探讨非小细胞肺癌患者血清癌胚抗原（carcinoembryonic antigen ，CEA）水平与EGFR-TKI治疗疗效之间的关系。方法 收集83例（腺癌67例，非腺癌16例）经吉非替尼或厄罗替尼治疗、疗效可评价的晚期非小细胞肺癌患者，有完整的血清CEA检测结果，分析CEA水平与EGFR-TKI药物治疗反应之间的关系。结果 血清CEA＜5ng/ml者的有效率(CR+PR)为15.6%(5/32)，稳定率 (SD)为18.8% (6/32)，进展率为65.6%（21/32）；CEA≥5ng/ml者的有效率为29.4%(15/51)，稳定率为45.1%（23/51）,进展率为25.5%（13/51）。两组EGFR-TKI治疗的疗效差异有显著统计学意义。血清CEA水平高的患者，服用TKI药物后疗效更好，而较低CEA值的患者效果较差。结论 血清CEA水平可作为预测非小细胞肺癌患者服用EGFR-TKI药物的疗效指标。 关键词: 癌胚抗原; EGFR酪氨酸激酶抑制剂; 吉非替尼; 厄洛替尼; 非小细胞肺癌 中图法分类号：R734.2 The serum CEA level is associated with the efficacy of EGFR-TKI treatment in non-small cell lung cancer. Li Xingya1, Cheng Yuan1, Liu Jie1, Zhang Zhongmian2, Zhou Yun3, Ma Zhiyong4, Shen Shujing5, Jia Yongxu1.（1Department of Medical Oncology，The First Affiliated Hospital of Zhengzhou University, Zhengzhou，450052, China; 2Department of Medical Oncology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China; 3Department of Medical Oncology, Peoples Hospital of Henan Province, Zhengzhou, 450052, China. 4Department of Medical Oncology, Tumor Hospital of Henan Province, Zhengzhou，450052, China; 5Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052，China.） Abstract: Objective EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor) as a gene targeted drug has been used for advanced NSCLC (non-small cell lung cancer). This study investigated the relationship between the serum CEA level and the therapeutic effect in advanced NSCLC treated with EGFR-TKI. Methods In this study, we retrospectively reviewed 83 NSCLC patients，including 67 adenocarcinoma and 16 non-adenocarcinoma. The therapeutic effect could be evaluated correctly and all cases had complete outcome of serum CEA. The statistical test between the serum CEA level and the therape